and inhibiting this enzyme has been found to benefit lymphoma patients even when they have non-mutant EZH2. An EZH2 inhibitor called tazemetostat was approved by the FDA in 2020 for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback